Nkarta posts updated corporate presentation; no specific material updates in filing excerpt

Nkarta, Inc.

Company made available an updated corporate presentation dated January 2024.
Presentation focuses on NK cell engineering for cancer and autoimmune diseases.
Filed exhibit contains only a title slide; no financial data or milestones provided.
Presentation is furnished under Regulation FD and not filed with the SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.